H.U. Group Holdings, Inc., together with its subsidiaries, operates healthcare business in Japan, the United States, Europe, and internationally. The Lab Testing and Its Related Services segment provides general testing services to medical institutions that include esoteric testing, such as genetic and oncology testing; diagnostics-related tests for cancer treatment; omics analysis comprising whole genome sequencing (WGS) and proteome analysis; support for clinical trials and research, including pre-trial setup work, specimen collection and transport, measuring, result reports, and data management, as well as SaaS for general practitioners and personal health records. Its In-Vitro Diagnostics segment provides Lumipulse system products, an automated chemiluminescence enzyme immunoassay system that offers reagents; testing services for neurodegenerative diseases; and diagnostics kit for infectious diseases comprising influenza and COVID-19, as well as cerebrospinal fluid reagent. This segment also develops blood-based reagents and biomarkers specifically for neurodegenerative diseases, such as Alzheimer's. The Healthcare-related Services segment offers in-house sterilization for central supply rooms in hospitals and external sterilization at sterilization centers; operating room support, endoscopy room support, medical equipment maintenance and inspection, and logistics management and transportation services; support for important tasks related to hospital administration work, including the sale of medical equipment, supplies, and consumables related to central supply rooms and operating rooms; and home medical care and nursing services. The company was formerly known as Miraca Holdings Inc. and changed its name to H.U. Group Holdings, Inc. in July 2020. H.U. Group Holdings, Inc. was incorporated in 1950 and is headquartered in Tokyo, Japan.
Research context
H.U. Group Holdings, Inc appears in PyInvesting’s Tokyo Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Diagnostics & Research
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
H.U. Group Holdings, Inc is currently in a long term downtrend where the price is trading 9.5% below its 200 day moving average.
From a valuation standpoint, the stock is 98.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.0.
H.U. Group Holdings, Inc's total revenue rose by 29.3% to $63B since the same quarter in the previous year.
Its net income has increased by 1206.7% to $8B since the same quarter in the previous year.
Finally, its free cash flow grew by 783.5% to $8B since the same quarter in the previous year.
Based on the above factors, H.U. Group Holdings, Inc gets an overall score of 4/5.